Introduction
============

Deafness is the most common sensory deficit disorder, accounting for a high incidence of disability ([@b1-etm-0-0-8890]). According to a survey from the World Health Organization (WHO) in 2013, there are \~360 million people with varying degrees of deafness worldwide ([@b2-etm-0-0-8890]). According to epidemiological data, \~1 in 1,000 newborns is diagnosed with congenital deafness ([@b3-etm-0-0-8890]). Deafness directly affects cognition, thinking and memory, resulting in a decline in the quality of life, thereby contributing to the burden of families and society ([@b4-etm-0-0-8890]). The progression and development of modern medicine have gradually reduced the proportion of deafness cases caused by environmental factors ([@b5-etm-0-0-8890]). However, the proportion of patients with hearing impairment caused by genetic factors has largely remained to be determined ([@b6-etm-0-0-8890]). Based on deafness combined with the presence or absence of malformations of the external ear, hereditary deafness may be classified into syndromic deafness and non-syndromic deafness ([@b7-etm-0-0-8890]). Nearly 70% of cases of hereditary deafness may be attributed to non-syndromic hearing loss (NSHL) and 50% of cases of NSHL have Mendelian disease ([@b8-etm-0-0-8890]). At present, \~145 chromosomal loci are known to be associated with non-syndromic deafness ([@b9-etm-0-0-8890]). The coagulation factor C homology (COCH) gene was the first gene to be identified to cause non-syndromic deafness (Online Mendelian Inheritance in Man ID, 603196) ([@b10-etm-0-0-8890]). Patients with a mutation in this gene may present with a series of symptoms caused by cochlear and vestibular dysfunction ([@b11-etm-0-0-8890]). At present, detection of the COCH mutation is a subject of intense research ([@b12-etm-0-0-8890]). Screening for gene mutations using traditional Sanger sequencing is time-consuming and expensive ([@b13-etm-0-0-8890]).

Recent developments in whole-exome sequencing (WES) technology have shifted this paradigm and currently, rapid sequencing of exomes, transcriptomes and genomes may be completed at a relatively low cost ([@b14-etm-0-0-8890]). Of note, the application of this technology to catalog the mutational landscapes of genetic disorders has revealed a novel approach to explore single-gene diseases ([@b15-etm-0-0-8890],[@b16-etm-0-0-8890]). The use of WES technology in patients with hereditary deafness and targeted next-generation sequencing of genes associated with deafness in hearing-impaired individuals has enabled the identification of informative mutations ([@b17-etm-0-0-8890]). WES is not only able to provide an efficient diagnosis for known deafness genes but also unravel novel gene mutations that may help us understand the molecular mechanism underlying deafness or hearing loss ([@b18-etm-0-0-8890]).

The present study aimed to identify genetic factors associated with hearing loss in a Chinese pedigree with hearing loss. WES was employed to identify a novel gene mutation in the gene crystallin µ (CRYM) that was accountable for the disease.

Materials and methods
=====================

### Subjects

The present study reported on familial non-syndromic autosomal dominant sensorineural deafness in four generations of a Chinese pedigree. The genealogical proband was a 35-year-old female, recruited from Xinqiao Hospital (Chongqing, China) of the Army Medical University in September 2015. This proband was subjected to pure-tone audiometry, Distortion Product Otoacoustic Emission (DPOAE) and Auditory Brainstem Response (ABR) evaluation. The test results were indicative of sensorineural deafness in the right ear and a high-frequency hearing loss in the left ear ([Fig. 1](#f1-etm-0-0-8890){ref-type="fig"}). The results presented a progressive aggravation of hearing loss with increasing frequency illustrated by a downsloping of the hearing curve. The patient was diagnosed with sensorineural deafness according to the guidelines for clinical evaluation and etiologic diagnosis of hearing loss by the American College of Medical Genetics and Genomics ([@b19-etm-0-0-8890]). The patient and her family members were enrolled in the present study. The study protocol was approved by the Ethics Committee of Xinqiao Hospital (Chongqing, China) and the study was performed in accordance with the Declaration of Helsinki. Written informed consent was obtained from the proband and the remaining family members. Furthermore, all of the participants agreed to the publication of their results on clinical characteristics and genetic data with protection of their privacy. Subsequently, the detailed medical history was collected, including family history of deafness and consanguineous marriages, year of onset of deafness, age, progression, and history of ototoxic drugs and noise exposure.

### DNA extraction

Whole blood samples of all subjects were collected and subjected to genomic DNA extraction using the RelaxGene Blood DNA System (Tiangen Biotech) as per the manufacturer\'s instructions. The extracted DNA was stored at -20˚C until further analysis.

### Audiology function examination

An audiology function examination was performed using pure tone audiometry, DPOAE and ABR on all family members using standard procedures as described previously ([@b20-etm-0-0-8890]).

### Gene chip detection analysis

A total of 15 mutations of four deafness-associated genes were detected, including those in gap junction protein beta 2 (GJB2; 35delG, 176del16, 235delC and 299delAT), GJB3 (538C\>T), solute carrier family 26 member 4 (2168A\>G, IVS7-2A\>G, 1174A\>T, 122G\>A, 1229C\>T, 1975G\>C, 2027T\>A and IVS15+5 G\>A) and mitochondrial 12S ribosomal RNA (1494C\>T and 1555A\>G) using the Heredity Hearing Loss Array Detection Kit purchased from Capital Bio Corp. The chip was imaged using a LuxScan™ 10 KB Microarray Scanner (Capital Bio Corp.) ([@b21-etm-0-0-8890]). Data evaluation was performed using SPSS 19.0 (IBM Corp.).

### WES analysis

Specific primer sequences were designed by Primer Premier 5.0 (Premier Biosoft International). The Ion PI™ Hi-Q™ Sequencing 200 Kit (Thermo Fisher Scientific, Inc.) was employed for target gene mutation detection by computational mapping analysis. Genomic DNA samples were sheared by sonication. The sheared genomic DNA was then hybridized with the NimbleGen 2.0 probe sequence capture array from Roche (<http://www.nimblegen.com/products/seqcap/ez/v2/index.html>) to enrich the exonic DNA (Joy Orient). The libraries were first tested for exon-enrichment by quantitative PCR and for size distribution and concentration using the Agilent Bioanalyzer 2100 (Agilent Technologies, Inc.). The samples were then sequenced on an Illumina Hiseq 2500 platform (Illumina, Inc.). Each sample was tested in two parallel reactions.

Results
=======

### Family investigation and clinical phenotype

The pedigree chart is presented in [Fig. 2](#f2-etm-0-0-8890){ref-type="fig"}. The family consisted of 31 members belonging to four generations. There were 14 males and 17 females. All family members underwent pure-tone audiometry examinations and the results are listed in [Table I](#tI-etm-0-0-8890){ref-type="table"}. A total of 7 patients, aged 31-79 years, were diagnosed with sensorineural deafness of varying degrees. None of the patients had a history of ototoxic drug exposure. Among them, cases I~1~, II~3~ and II~4~ were diagnosed with severe deafness on both ears. Cases III~2~, III~9~ and III~14~ demonstrated mild sensorineural deafness. Case II~6~ had mixed deafness (conductive deafness and sensory deafness) on the right ear and sensorineural deafness on the left ear. The results of the hearing test for the remaining family members are listed in Supplementary [Table SI](#SD1-etm-0-0-8890){ref-type="supplementary-material"}. There was no predilection for sex and a significant phenomenon of continuous transmission was noted. At least one parent of affected subjects was diagnosed with deafness, suggesting that the disease had an autosomal dominant pattern of inheritance.

### Gene chip identification of deafness-associated genes

The routine diagnosis of deafness genes was performed by microarray in order to identify hot mutations in the study subjects. The gene chip contained 4 genes and 15 loci. The details of the gene chip and the mutations it is able to detect are listed in [Table II](#tII-etm-0-0-8890){ref-type="table"}. However, none of these mutations was identified by the gene chip in any of the participants.

### Mutation identified by WES

WES was performed in four family members, namely cases III~2~, III~14~, IV~2~ and IV~8~. A heterozygous mutation of CRYM was detected in cases III~2~ and III~14~; however, it was absent in subjects IV~2~ and IV~8~. The heterozygous mutation detected was c.152C\>T(Pro51Leu). However, no mutations in other known genes associated with deafness were observed. Whether the mutation was pathogenic and accounted for a familial trait remain to be verified. Sanger sequencing was used to verify the results obtained by WES in the remaining family members participating in the study. Of note, the CRYM mutation was identified in all other seven family members with deafness, as in the proband III~2~ ([Fig. 3](#f3-etm-0-0-8890){ref-type="fig"}).

### Bioinformatics analysis

PolyPhen-2 (<http://genetics.bwh.harvard.edu/pph2/>) was used to predict the possible impact of an amino acid substitution on the structure and function of the mutation, which indicated that the CRYM c.152C\>T(Pro51Leu) mutation is probably damaging, with a score of 1.000 (sensitivity, 0.00; specificity, 1.00), and the Protein Variation Effect Analyzer (<http://provean.jcvi.org/index.php>) indicated a deleterious effect with a score of -5.395 (score below -2.5 means deleterious effect). Collectively, these results strongly indicated that the p.P51L mutation was likely to be deleterious to the protein. The result of a multiple sequence alignment suggested that the proline at position 51 of CRYM is highly conserved among various species ([Fig. 4](#f4-etm-0-0-8890){ref-type="fig"}). In addition, the 3-dimensional protein structures were predicted and displayed with a cartoon, a cartoon/spheres and a surface model, which were generated using PyMOL software (version 2.3; Schrödinger LLC; [Fig. 5](#f5-etm-0-0-8890){ref-type="fig"}). The protein structure parameters indicated that The Inertia Axis Aligned Bounding Box (IABB) dimensions were (43.63, 47.33, 63.49) and (43.32, 47.22, 63.49) and the IABB volume was 131,101.14 and 129,861.34 for the wild-type and muted type, respectively. This indicates that this substitution is able to destabilize the protein conformation.

### Follow-up

The only follow-up of the proband was by a phone call after 4 years. The subjective sensation of her hearing was not significantly changed according to the telephone survey and answered a subjective questionnaire with the help of her family member. No further hearing examinations were completed on the other family members and no family members were prescribed hearing aids.

Discussion
==========

In the present study, a Chinese pedigree with hereditary sensorineural hearing loss of unknown genetic etiology was analyzed for a causative mutation using WES. A novel mutation, NM_00188.5(CRYM): c.152C\>T(Pro51Leu), was detected. This mutation, not being a common variant, has a high likelihood of being pathogenic in patients with sensorineural hearing loss.

Deafness is a hereditary disorder with a high degree of genetic heterogeneity. DFNA is primarily the result of a single gene mutation ([@b22-etm-0-0-8890]). To date, a total of 105 genes have been reported to be associated with NSHL ([@b23-etm-0-0-8890]). Among the genes linked to this condition, COCH was the first gene to be reported to be associated with vestibular function ([@b24-etm-0-0-8890]). Clinical symptoms of COCH mutation are autosomal dominant, non-syndromic and characterized by progressive sensorineural hearing loss ([@b10-etm-0-0-8890]). At onset, the disease involves high-frequency hearing impairment. It progresses with age to severe hearing loss affecting low and high frequencies ([@b25-etm-0-0-8890]).

Recently, with the advent of comprehensive genetic testing for hereditary hearing loss using massively parallel sequencing ([@b26-etm-0-0-8890]), further gene mutations accounting for NSHL have been identified, thereby highlighting its genetic heterogeneity ([@b27-etm-0-0-8890]). The application of a deafness diagnostic screening panel based on a deafness mutations/gene database has gained popularity ([@b28-etm-0-0-8890]). A gene diagnostic chip for hereditary deafness has been used previously to detect gene mutations associated with hearing impairment among high-risk pregnant females ([@b29-etm-0-0-8890]) and newborns ([@b30-etm-0-0-8890]), and for pre-natal diagnosis of deafness to avoid the birth of children with congenital deafness ([@b31-etm-0-0-8890]).

At present, gene chip is used for rapid genetic diagnosis and in epidemiological surveys of hearing loss. However, it was originally devised for hot-spot mutations that have already been reported. Therefore, it cannot be used to detect other mutations in these genes. With the rapid development of WES technology, the scientific community has begun to widely adopt second-generation sequencing technology to solve biological problems. This novel generation of sequencers is able to rapidly sequence whole genomes and zoom in to deeply sequence the target regions of interest ([@b32-etm-0-0-8890]). Numerous genetic variants of unknown significance may be detected in patients by WES. In the present study, a regular gene chip was used to screen mutations for hearing loss, although no positive results were obtained. However, with the application of NGS, a novel mutation of CRYM, c.152C\>T(Pro51Leu), responsible for hearing impairment was identified.

CRYM, which is also termed Thyroid Hormone Binding Protein (THBP) or Deafness, autosomal dominant, 40 (DFNA40), is located on chromosome 16. Its transcript length is 1,482 bp with eight exons encoding 314 amino acids. CRYM is mainly expressed in the heart and brain. It is particularly abundant in the inner ear ([@b33-etm-0-0-8890]). A previous study has demonstrated that CRYM is expressed in the human cochlea ([@b34-etm-0-0-8890]). CRYM has a critical role in the physiological regulation of the activity of thyroid hormone ([@b35-etm-0-0-8890]). An experimental study has indicated that CRYM may have a role in the development of cortical and hippocampal pyramidal cells in the early postnatal period ([@b36-etm-0-0-8890]). Furthermore, CRYM expression is possibly upregulated through the activator protein-1 (AP-1) site in the promoter ([@b37-etm-0-0-8890]). Another important CRYM function has also been identified: When combined with ketimine reductase, it may act as a classical imine reductase ([@b38-etm-0-0-8890]). In addition, CRYM has a critical role and is regarded as a novel androgen-regulated gene whose expression is elevated in prostate cancer ([@b39-etm-0-0-8890]). It has been demonstrated in an animal model that CRYM mutations cause auditory dysfunction through thyroid hormone-binding effects on the cochlea ([@b40-etm-0-0-8890]). It is well known that thyroid hormone is crucial for normal development, as well as maintenance of hearing function ([@b41-etm-0-0-8890]). CRYM is divided into two classes: Taxon-specific and ubiquitous. This gene encodes a taxon-specific crystallin protein that binds NADPH and has a sequence similarity to bacterial ornithine cyclodeaminases, which is particularly abundant in kangaroo lenses ([@b42-etm-0-0-8890]).

To date, CRYM-null patients have not been reported ([@b35-etm-0-0-8890]). Abe *et al* ([@b43-etm-0-0-8890]) were the first to demonstrate that CRYM mutation is associated with hearing loss. In their study, they indicated that one missense and one stop-lost variant in CRYM was a pathogenic mutation for hearing loss in two different families of Japanese origin. A search for the CRYM mutation in Clinvar was performed (<https://www.ncbi.nlm.nih.gov/clinvar/?term=CRYM%5Bgene%5D>). Most of the identified mutations in other loci of CRYM were benign, of uncertain significance or had conflicting interpretations of pathogenicity. The details of the mutations identified are listed in [Table III](#tIII-etm-0-0-8890){ref-type="table"}. The previously unreported novel CRYM mutation identified in the present study is likely to be pathogenic.

In conclusion, the present study identified a novel mutation, NM_00188.5(CRYM): c.152C\>T(Pro51Leu), which further strengthened the association between CRYM mutation and NSHL. Further functional studies regarding mutations in this clinical condition may assist in clarifying the pathogenic mechanism underlying familial sensorineural deafness.

Supplementary Material
======================

###### Hearing testing results of the family members without clinical symptoms.

Not applicable.

Funding
=======

No funding received.

Availability of data and materials
==================================

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Authors\' contributions
=======================

AD designed the study; QL performed all of the experiments; XZ and JY carried out the audiology function examination; MW collected the clinical data, analyzed the data, and prepared the manuscript. All authors have read and approved the final version of the manuscript.

Ethics approval and consent to participate
==========================================

The study protocol was approved by the Ethics Committee of Xinqiao Hospital (Chongqing, China) and the study was performed in accordance with the Declaration of Helsinki. Written informed consent was obtained from the proband and the remaining family members.

Patient consent for publication
===============================

All of the participants agreed to the publication of their results on clinical characteristics and genetic data with protection of their privacy.

Competing interests
===================

The authors declare that they have no competing interests.

![Results of the audiogram function test for the proband. dB, decibels; HL, hearing level.](etm-20-02-1447-g00){#f1-etm-0-0-8890}

![Pedigree chart of the family with the c.152C\>T mutation in CRYM.](etm-20-02-1447-g01){#f2-etm-0-0-8890}

![Results of the direct Sanger sequencing of the crystallin µ gene in seven patients with dominant sensorineural deafness. The mutation site is indicated by black arrows.](etm-20-02-1447-g02){#f3-etm-0-0-8890}

![Conservation analysis of the crystallin µ gene. The mutation site is indicated by a black arrow. WT, wild-type; Mu, mutant.](etm-20-02-1447-g03){#f4-etm-0-0-8890}

![Display of the predicted 3-dimensional protein structure of CRYM. The red colour indicated the amino acid mutation site. CRYM, crystallin µ.](etm-20-02-1447-g04){#f5-etm-0-0-8890}

###### 

Clinical characteristics of the family members.

  Subject   Age (years)   Sex      Age at onset (years)   Pure tone test                                                                 Degree of hearing loss        DPOAE                                                     Binaural ABR threshold (dBnHL)
  --------- ------------- -------- ---------------------- ------------------------------------------------------------------------------ ----------------------------- --------------------------------------------------------- --------------------------------
  I1        78            Male     47                     Binaural full frequency sensorineural deafness                                 High severity on both sides   Binaural full frequency extraction in abnormal range      110
  II2       56            Male     54                     Binaural sensorineural deafness                                                Moderate on both sides        Binaural full frequency extraction in abnormal range      50
  II3       61            Female   52                     Binaural mixed deafness                                                        Severe on both sides          Binaural full frequency extraction in abnormal range      70
  II4       56            Male     43                     Binaural sensorineural deafness                                                Severe on both sides          Binaural full frequency extraction in abnormal range      100
  II6       56            Male     50                     Binaural mixed deafness                                                        Severe on both sides          Binaural full frequency extraction in abnormal range      70
  III2      35            Female   32                     Sensorineural deafness in right ear, high-frequency hearing loss in left ear   Normal hearing threshold      Binaural partial frequency extraction in abnormal range   30
  III9      31            Male     31                     Binaural sensorineural deafness with high frequency                            Normal hearing threshold      Binaural partial frequency extraction in abnormal range   30
  III14     32            Female   31                     Binaural sensorineural deafness with high frequency                            Normal hearing threshold      Binaural partial frequency extraction in abnormal range   40

DPOAE, Distortion Product Otoacoustic Emission; ABR, Auditory Brainstem Response; dBnHL, decibel normal hearing level.

###### 

General deafness gene chip for target capture.

  Gene      Variant
  --------- --------------------------
  GJB2      NM_004004.6:c.35delG
  GJB2      176del16
  GJB2      235delC
  GJB2      299delAT
  GJB3      NM_024009.3:c.538C\>T
  SLC26A4   2168A\>G
  SLC26A4   NM_000441.2:c.919-2A\>G
  SLC26A4   1174A\>T
  SLC26A4   1226G\>A
  SLC26A4   1229C\>T
  SLC26A4   1975G\>C
  SLC26A4   2027T\>A
  SLC26A4   NM_000441.2:c.1707+5G\>A
  MT-RNR1   1494C\>T
  MT-RNR1   1555A\>G

GJB2, gap junction protein β 2; SLC26A4, solute carrier family 26 member 4; MT-RNR1, mitochondrially encoded 12S ribosomal RNA.

###### 

Summary of mutations in the crystallin µ gene and the clinical significance of pedigrees with associated dominant sensorineural deafness.

  Nucleic acid mutation   Amino acid variation   Molecular consequence       Clinical significance
  ----------------------- ---------------------- --------------------------- ----------------------------------------------
  c.945A\>T               p.Ter315Tyr            Single nucleotide variant   Pathogenic
  c.941A\>C               p.Lys314Thr            Missense                    Pathogenic
  c.907G\>A               p.Ala303Thr            Missense                    Uncertain significance
  c.864C\>G               p.Thr288=              Single nucleotide variant   Benign
  c.807T\>C               p.Phe269=              Single nucleotide variant   Benign/likely benign
  c.761C\>T               p.Ala254Val            Missense                    Uncertain significance
  c.741C\>T               p.Tyr247=              Single nucleotide variant   Benign
  c.662C\>T               p.Ala221Val            Missense                    Likely benign
  c.580G\>A               p.Ala194Thr            Missense                    Uncertain significance
  c.523_524delinsTT       p.Glu175Leu            Missense                    Conflicting interpretations of pathogenicity
  c.490-12C\>T                                   Single nucleotide variant   Benign
  c.489+9A\>G                                    Single nucleotide variant   Likely benign
  c.480C\>T               p.Ser160=              Single nucleotide variant   Likely benign
  c.479C\>T               p.Ser160Phe            Missense                    Uncertain significance
  c.474G\>A               p.Gln158=              Single nucleotide variant   Uncertain significance
  c.343A\>G               p.Ile115Val            Missense                    Uncertain significance
  c.325-12T\>C                                   Single nucleotide variant   Benign
  c.279G\>A               p.Gln93=               Single nucleotide variant   Likely benign
  c.135C\>A               p.Pro45=               Single nucleotide variant   Likely benign
  c.108C\>A               p.Ser36Arg             Missense                    Conflicting interpretations of pathogenicity
  c.8G\>T                 p.Arg3Leu              Missense                    Uncertain significance
